Overview

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Status:
Active, not recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Acerta Pharma BV
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Acalabrutinib
Pembrolizumab